Burmese pythons have pretty irregular eating habits. One of these giant reptiles can swallow an entire antelope whole and then go up to a year and a half without additional meals. Now, scientists have ...

Lanre Dokun, a psychiatrist in New York, has a lot of clients with financial anxiety. For the older ones, the stress is usually situational: Perhaps they’ve lost their job, or they’re worrying about ...

With AI, you can generate dozens (if not hundreds) of articles in hours and publish at scale. But publishing is the easy part. What happens after they go live is what matters. Together with the ...

Crimson Desert just launched yesterday to a bit of a chaotic and mixed reception from critics. That hasn't hampered its sales, but those two million players are starting to stumble into some ...

Claude can now generate visuals when producing a response. (Anthropic) With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its ...

Forbes contributors publish independent expert analyses and insights. Vibhas Ratanjee studies leadership and culture at Gallup This voice experience is generated by AI. Learn more. This voice ...

The country’s highest judicial court won’t reconsider a decision that determined AI-created art is ineligible for copyright protection. The country’s highest judicial court won’t reconsider a decision ...

The workplace can be a tricky place to navigate. Almost everything we do at work—identifying the experts, managing tough feedback from a boss, figuring out how to work in teams made up of different ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Gucci's use of AI-generated images ahead of its Milan runway show has sparked debate. Social media users have called the images "tacky" and "cheap." Experts say this is a strategic move by Gucci to ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...